{
    "paper_id": "0a66c4f25cf2a0a97fd40b82cf1d9f3f17b811b5",
    "metadata": {
        "title": "Journal Pre-proof Impact de la pand\u00e9mie du SARS-CoV-2 sur l'oed\u00e8me maculaire diab\u00e9tique et facteurs pronostiques",
        "authors": [
            {
                "first": "Khodriss",
                "middle": [],
                "last": "Chaimae",
                "suffix": "",
                "affiliation": {
                    "laboratory": "m\u00e9decine et de pharmacie de F\u00e8s. Universit\u00e9 Sidi Mohamed Ben Abdellah. \uf0fc Adresse",
                    "institution": "Universit\u00e9 Sidi Mohamed Ben Abdellah",
                    "location": {}
                },
                "email": ""
            },
            {
                "first": "Ibtissam",
                "middle": [],
                "last": "El",
                "suffix": "",
                "affiliation": {
                    "laboratory": "m\u00e9decine et de pharmacie de F\u00e8s. Universit\u00e9 Sidi Mohamed Ben Abdellah. \uf0fc Adresse",
                    "institution": "Universit\u00e9 Sidi Mohamed Ben Abdellah",
                    "location": {}
                },
                "email": ""
            },
            {
                "first": "Harch",
                "middle": [],
                "last": "Bennis",
                "suffix": "",
                "affiliation": {
                    "laboratory": "m\u00e9decine et de pharmacie de F\u00e8s. Universit\u00e9 Sidi Mohamed Ben Abdellah. \uf0fc Adresse",
                    "institution": "Universit\u00e9 Sidi Mohamed Ben Abdellah",
                    "location": {}
                },
                "email": ""
            },
            {
                "first": "Ahmed",
                "middle": [
                    "Chraibi"
                ],
                "last": "Fouad",
                "suffix": "",
                "affiliation": {
                    "laboratory": "m\u00e9decine et de pharmacie de F\u00e8s. Universit\u00e9 Sidi Mohamed Ben Abdellah. \uf0fc Adresse",
                    "institution": "Universit\u00e9 Sidi Mohamed Ben Abdellah",
                    "location": {}
                },
                "email": ""
            },
            {
                "first": "Samira",
                "middle": [],
                "last": "El",
                "suffix": "",
                "affiliation": {
                    "laboratory": "m\u00e9decine et de pharmacie de F\u00e8s. Universit\u00e9 Sidi Mohamed Ben Abdellah. \uf0fc Adresse",
                    "institution": "Universit\u00e9 Sidi Mohamed Ben Abdellah",
                    "location": {}
                },
                "email": ""
            },
            {
                "first": "Fakir",
                "middle": [],
                "last": "Abdellaoui",
                "suffix": "",
                "affiliation": {
                    "laboratory": "m\u00e9decine et de pharmacie de F\u00e8s. Universit\u00e9 Sidi Mohamed Ben Abdellah. \uf0fc Adresse",
                    "institution": "Universit\u00e9 Sidi Mohamed Ben Abdellah",
                    "location": {}
                },
                "email": ""
            },
            {
                "first": "Meryem",
                "middle": [],
                "last": "Nabil",
                "suffix": "",
                "affiliation": {
                    "laboratory": "m\u00e9decine et de pharmacie de F\u00e8s. Universit\u00e9 Sidi Mohamed Ben Abdellah. \uf0fc Adresse",
                    "institution": "Universit\u00e9 Sidi Mohamed Ben Abdellah",
                    "location": {}
                },
                "email": ""
            },
            {
                "first": "Tachfouti",
                "middle": [],
                "last": "Benatiya",
                "suffix": "",
                "affiliation": {
                    "laboratory": "m\u00e9decine et de pharmacie de F\u00e8s. Universit\u00e9 Sidi Mohamed Ben Abdellah. \uf0fc Adresse",
                    "institution": "Universit\u00e9 Sidi Mohamed Ben Abdellah",
                    "location": {}
                },
                "email": ""
            },
            {
                "first": "Andaloussi",
                "middle": [],
                "last": "Idriss",
                "suffix": "",
                "affiliation": {
                    "laboratory": "m\u00e9decine et de pharmacie de F\u00e8s. Universit\u00e9 Sidi Mohamed Ben Abdellah. \uf0fc Adresse",
                    "institution": "Universit\u00e9 Sidi Mohamed Ben Abdellah",
                    "location": {}
                },
                "email": ""
            }
        ]
    },
    "abstract": [
        {
            "text": "J o u r n a l P r e -p r o o f Impact de la pand\u00e9mie du SARS-CoV-2 sur l'oed\u00e8me maculaire diab\u00e9tique et facteurs pronostiques.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Titre en fran\u00e7ais : Impact de la pand\u00e9mie du SARS-CoV-2 sur l'oed\u00e8me maculaire diab\u00e9tique et facteurs pronostiques.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Titre en anglais : Impact of the SARS-CoV-2 pandemic on diabetic macular edema and prognostic factors.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Titre court : oed\u00e8me maculaire diab\u00e9tique et pand\u00e9mie de la COVID 19",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "L'OMD est l'une des principales causes de baisse d'acuit\u00e9 visuelle chez les patients diab\u00e9tiques. [3] Les injections intravitr\u00e9ennes d'anti-VEGF associ\u00e9es \u00e0 l'\u00e9quilibre des facteurs syst\u00e9miques constituent un outil indispensable dans la prise en charge de l'OMD. [4, 5] Cependant, la compliance au traitement ainsi que des injections r\u00e9guli\u00e8res sont n\u00e9cessaires afin d'obtenir un b\u00e9n\u00e9fice th\u00e9rapeutique. [6] Le but de cette \u00e9tude est de d\u00e9crire les cons\u00e9quences fonctionnelles et structurelles de l'arr\u00eat des injections intravitr\u00e9ennes chez les patients avec OMD. Et d'\u00e9tudier les diff\u00e9rents facteurs qui peuvent \u00eatre associ\u00e9s \u00e0 cette aggravation au cours de l'arr\u00eat des injections intra-vitr\u00e9ennes. Le niveau de signification a \u00e9t\u00e9 fix\u00e9 \u00e0 5% et l'analyse statistique a \u00e9t\u00e9 r\u00e9alis\u00e9e \u00e0 l'aide du logiciel R.",
            "cite_spans": [
                {
                    "start": 98,
                    "end": 101,
                    "text": "[3]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 263,
                    "end": 266,
                    "text": "[4,",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 267,
                    "end": 269,
                    "text": "5]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 404,
                    "end": 407,
                    "text": "[6]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Nos patients ont \u00e9t\u00e9 inform\u00e9s que leurs donn\u00e9es seront le sujet d'une \u00e9tude, ainsi nous avons recueilli leur consentement \u00e9clair\u00e9. N\u00e9anmoins, plusieurs ophtalmologues ont rapport\u00e9 leur exp\u00e9rience d'administration des injections intravitr\u00e9ennes au cours de la premi\u00e8re vague de la pand\u00e9mie en respectant les mesures de protection et en impl\u00e9mentant certaines modifications \u00e0 leur pratique. [12, 13] Une diminution du nombre d'injections intravitr\u00e9ennes administr\u00e9es au cours de la pand\u00e9mie a \u00e9t\u00e9 observ\u00e9e dans la plupart des pays. [14] Billioti et al a rapport\u00e9 une diminution de 47.1% du nombre d'injections intravitr\u00e9ennes durant les 5 premi\u00e8res semaines de confinement en France. [15] En Italie J o u r n a l P r e -p r o o f une r\u00e9duction allant de 60% \u00e0 91,7% a \u00e9t\u00e9 observ\u00e9e. [11, 16] Alors qu'en Israel, Wasser et al a objectiv\u00e9 une r\u00e9duction de 36%. [17] L'adh\u00e9rence et la compliance aux traitements constituent un \u00e9l\u00e9ment essentiel dans la prise en charge du patient diab\u00e9tique. [18] Egalement, l'administration r\u00e9guli\u00e8re des injections intravitr\u00e9ennes d'anti-VEGF est n\u00e9cessaire pour l'obtention d'une am\u00e9lioration fonctionnelle. [19] [20] [21] Ind\u00e9pendamment du contexte pand\u00e9mique, il a \u00e9t\u00e9 d\u00e9montr\u00e9 que les interruptions r\u00e9p\u00e9t\u00e9es des injections intravitr\u00e9ennes entrainent de mauvais r\u00e9sultats structurels et fonctionnels. [22] Weiss et al a m\u00eame rapport\u00e9 une mauvaise observance aux injections intravitr\u00e9ennes des patients diab\u00e9tiques par rapport aux patients trait\u00e9s pour DMLA, avec des r\u00e9sultats fonctionnels m\u00e9diocres secondaires \u00e0 la mauvaise compliance th\u00e9rapeutique. [6] Le retard d'administration des injections intravitr\u00e9ennes au cours de la pand\u00e9mie a caus\u00e9 une aggravation fonctionnelle chez 44,8% des sujets de notre \u00e9tude, alors que l'aggravation structurelle a \u00e9t\u00e9 not\u00e9e chez 26,6%. Ashkenazy a rapport\u00e9 une aggravation de l'acuit\u00e9 visuelle et de l'\u00e9paisseur centromaculaire chez les patients qui ont rat\u00e9 leurs injections en comparaison avec ceux qui les ont re\u00e7ues \u00e0 temps. [23] Song et al a m\u00eame rapport\u00e9 une aggravation de l'acuit\u00e9 visuelle plus importante chez les patients diab\u00e9tiques qui ont rat\u00e9 ou annul\u00e9 leurs injections au cours de la pand\u00e9mie. [24] Narvane et al n'a pas observ\u00e9 d'aggravation fonctionnelle significative chez les patients trait\u00e9s pour OMD dont les injections ont \u00e9t\u00e9 report\u00e9es de plus de deux semaines, alors qu'il a not\u00e9 une aggravation structurelle. [25] Contrairement \u00e0 Elfalah et al qui a rapport\u00e9 une am\u00e9lioration fonctionnelle (p=0,045) apr\u00e8s un report des injections d'une dur\u00e9e de 60.97 (\u00b1 24.35) jours, alors qu'une aggravation a \u00e9t\u00e9 constat\u00e9e chez les yeux avec DMLA. [26] A notre connaissance, peu d'\u00e9tudes ont \u00e9valu\u00e9 les facteurs pouvant \u00eatre associ\u00e9s \u00e0 l'aggravation constat\u00e9e chez les patients qui ont rat\u00e9 leurs injections intravitr\u00e9ennes au cours de la pand\u00e9mie.",
            "cite_spans": [
                {
                    "start": 389,
                    "end": 393,
                    "text": "[12,",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 394,
                    "end": 397,
                    "text": "13]",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 530,
                    "end": 534,
                    "text": "[14]",
                    "ref_id": "BIBREF17"
                },
                {
                    "start": 682,
                    "end": 686,
                    "text": "[15]",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 780,
                    "end": 784,
                    "text": "[11,",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 785,
                    "end": 788,
                    "text": "16]",
                    "ref_id": null
                },
                {
                    "start": 856,
                    "end": 860,
                    "text": "[17]",
                    "ref_id": "BIBREF21"
                },
                {
                    "start": 986,
                    "end": 990,
                    "text": "[18]",
                    "ref_id": "BIBREF23"
                },
                {
                    "start": 1138,
                    "end": 1142,
                    "text": "[19]",
                    "ref_id": "BIBREF24"
                },
                {
                    "start": 1143,
                    "end": 1147,
                    "text": "[20]",
                    "ref_id": "BIBREF25"
                },
                {
                    "start": 1148,
                    "end": 1152,
                    "text": "[21]",
                    "ref_id": "BIBREF27"
                },
                {
                    "start": 1333,
                    "end": 1337,
                    "text": "[22]",
                    "ref_id": "BIBREF29"
                },
                {
                    "start": 1584,
                    "end": 1587,
                    "text": "[6]",
                    "ref_id": null
                },
                {
                    "start": 2000,
                    "end": 2004,
                    "text": "[23]",
                    "ref_id": "BIBREF30"
                },
                {
                    "start": 2180,
                    "end": 2184,
                    "text": "[24]",
                    "ref_id": "BIBREF31"
                },
                {
                    "start": 2405,
                    "end": 2409,
                    "text": "[25]",
                    "ref_id": "BIBREF32"
                },
                {
                    "start": 2631,
                    "end": 2635,
                    "text": "[26]",
                    "ref_id": "BIBREF34"
                }
            ],
            "ref_spans": [],
            "section": "Le cadre \u00e9thique"
        },
        {
            "text": "Dans l'\u00e9tude d'Elfalah et al, l'aggravation \u00e9tait li\u00e9e \u00e0 la dur\u00e9e d'arr\u00eat des injections ainsi qu'au nombre d'injections re\u00e7ues. Les patients ayant re\u00e7u au pr\u00e9alable plus de 3 injections avaient une d\u00e9t\u00e9rioration plus significative de l'acuit\u00e9 visuelle par rapport aux patients qui ont re\u00e7u moins. [26] Nos r\u00e9sultats ont montr\u00e9 que le taux d'aggravation \u00e9tait plus important chez les patients ayant re\u00e7u un faible nombre d'injections en pr\u00e9-confinement. Plusieurs \u00e9tudes ont \u00e9galement montr\u00e9 une relation positive entre le nombre d'injections d'anti-VEGF re\u00e7ues et l'am\u00e9lioration fonctionnelle. [27] Nous avons \u00e9galement objectiv\u00e9 que l'aggravation fonctionnelle est associ\u00e9e au d\u00e9s\u00e9quilibre glyc\u00e9mique. Apr\u00e8s le confinement on a observ\u00e9 l'apparition d'un d\u00e9s\u00e9quilibre glyc\u00e9mique chez 50,9% des patients. Ce d\u00e9s\u00e9quilibre peut \u00eatre associ\u00e9 au confinement puisque les consultations d'endocrinologie ont \u00e9t\u00e9 report\u00e9es dans plusieurs centres dans la r\u00e9gion.",
            "cite_spans": [
                {
                    "start": 298,
                    "end": 302,
                    "text": "[26]",
                    "ref_id": "BIBREF34"
                },
                {
                    "start": 595,
                    "end": 599,
                    "text": "[27]",
                    "ref_id": "BIBREF35"
                }
            ],
            "ref_spans": [],
            "section": "Le cadre \u00e9thique"
        },
        {
            "text": "L'association entre d\u00e9s\u00e9quilibre glyc\u00e9mique et aggravation de l'OMD n'est pas sp\u00e9cifique au contexte de la pand\u00e9mie puisqu'elle a \u00e9t\u00e9 \u00e9tablie comme \u00e9l\u00e9ment de r\u00e9ponse th\u00e9rapeutique. [28] Mais elle pourrait expliquer l'aggravation constat\u00e9e ind\u00e9pendamment de l'arr\u00eat des injections.",
            "cite_spans": [
                {
                    "start": 182,
                    "end": 186,
                    "text": "[28]",
                    "ref_id": "BIBREF36"
                }
            ],
            "ref_spans": [],
            "section": "Le cadre \u00e9thique"
        },
        {
            "text": "Cette \u00e9tude pr\u00e9sente comme limites l'absence de suivi \u00e0 long terme des patients ainsi que sa r\u00e9alisation en monocentrique. Mais malgr\u00e9 ces limites, elle nous a permis de quantifier l'aggravation et d'objectiver les facteurs li\u00e9s \u00e0 cette aggravation.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Le cadre \u00e9thique"
        },
        {
            "text": "Le report des injections intravitr\u00e9ennes au cours du confinement a eu des effets n\u00e9gatifs sur l'acuit\u00e9 visuelle et l'\u00e9paisseur centromaculaire des yeux avec OMD. Ces r\u00e9sultats sugg\u00e8rent d'\u00e9viter un report prolong\u00e9 des injections intravitr\u00e9ennes d'anti-VEGF chez les patients diab\u00e9tiques. N\u00e9anmoins, le suivi \u00e0 long terme ainsi que d'autres \u00e9tudes sont n\u00e9cessaires afin de confirmer ces r\u00e9sultats.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conclusion :"
        },
        {
            "text": "Les auteurs d\u00e9clarent ne pas avoir de conflits d'int\u00e9r\u00eat.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "D\u00e9claration des liens d'int\u00e9r\u00eat :"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "OEd\u00e8me maculaire diab\u00e9tique : aspects cliniques et prise en charge th\u00e9rapeutique",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Guigner",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Gaucher",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Intravitreal Aflibercept for Diabetic Macular Edema",
            "authors": [
                {
                    "first": "J-F",
                    "middle": [],
                    "last": "Korobelnik",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "V"
                    ],
                    "last": "Do",
                    "suffix": ""
                },
                {
                    "first": "U",
                    "middle": [],
                    "last": "Schmidt-Erfurth",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "S"
                    ],
                    "last": "Boyer",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [
                        "G"
                    ],
                    "last": "Holz",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "S"
                    ],
                    "last": "Heier",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Ophthalmology",
            "volume": "121",
            "issn": "",
            "pages": "2247--54",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Ranibizumab for Diabetic Macular Edema",
            "authors": [
                {
                    "first": "Q",
                    "middle": [
                        "D"
                    ],
                    "last": "Nguyen",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "M"
                    ],
                    "last": "Brown",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "M"
                    ],
                    "last": "Marcus",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "S"
                    ],
                    "last": "Boyer",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Patel",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Feiner",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Ophthalmology",
            "volume": "119",
            "issn": "",
            "pages": "789--801",
            "other_ids": {
                "DOI": [
                    "10.1016/j.ophtha.2011.12.039"
                ]
            }
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Facing COVID-19 in Ophthalmology Department",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "R"
                    ],
                    "last": "Romano",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Montericcio",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Montalbano",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Raimondi",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Allegrini",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Ricciardelli",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Curr Eye Res",
            "volume": "45",
            "issn": "",
            "pages": "653--661",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Diabetes and COVID-19: A systematic review on the current evidences",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Abdi",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Jalilian",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "A"
                    ],
                    "last": "Sarbarzeh",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Vlaisavljevic",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Diabetes Res Clin Pract",
            "volume": "166",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic",
            "authors": [
                {
                    "first": "J-F",
                    "middle": [],
                    "last": "Korobelnik",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Loewenstein",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Eldem",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "M"
                    ],
                    "last": "Joussen",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Koh",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "N"
                    ],
                    "last": "Lambrou",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Graefes Arch Clin Exp Ophthalmol",
            "volume": "2020",
            "issn": "",
            "pages": "1--8",
            "other_ids": {
                "DOI": [
                    "10.1007/s00417-020-04703-x"
                ]
            }
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Quelle conduite \u00e0 tenir adopter vis \u00e0 vis des injections intravitr\u00e9ennes (IVT) dans cette p\u00e9riode d'\u00e9pid\u00e9mie au Covid-19 -SARS-CoV-2 ?",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Kodjikian",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Fr Ophtalmol",
            "volume": "43",
            "issn": "",
            "pages": "539--579",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "Intravitreal injections during COVID-19 outbreak: Real-world experience from an Italian tertiary referral center",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Carnevali",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Giannaccare",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Gatti",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Scuteri",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Randazzo",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Scorcia",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "European Journal of Ophthalmology",
            "volume": "31",
            "issn": "",
            "pages": "10--12",
            "other_ids": {
                "DOI": [
                    "10.1177/1120672120962032"
                ]
            }
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "Clinical Experience in the Administration of Intravitreal Injection Therapy at a Tertiary University Hospital",
            "authors": [
                {
                    "first": "O",
                    "middle": [
                        "A"
                    ],
                    "last": "Saleh",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Jammal",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Alqudah",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Alqudah",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Abu-Yaghi",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "Managing intravitreal injections in adults in COVID-19 and post-COVID-19 era-Initial experiences",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Agarwal",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Kumar",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Indian J Ophthalmol",
            "volume": "68",
            "issn": "",
            "pages": "1216--1224",
            "other_ids": {
                "DOI": [
                    "10.4103/ijo.IJO_1391_20"
                ]
            }
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "Early impact of COVID-19 outbreak on eye care: Insights from EUROCOVCAT group",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Toro",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "P"
                    ],
                    "last": "Br\u00e9zin",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Burdon",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "B"
                    ],
                    "last": "Cummings",
                    "suffix": ""
                },
                {
                    "first": "Evren",
                    "middle": [],
                    "last": "Kemer",
                    "suffix": ""
                },
                {
                    "first": "O",
                    "middle": [],
                    "last": "Malyugin",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "E"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "European Journal of Ophthalmology",
            "volume": "31",
            "issn": "",
            "pages": "5--9",
            "other_ids": {
                "DOI": [
                    "10.1177/1120672120960339"
                ]
            }
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "Intravitreal Anti-Vascular Endothelial Growth Factor Use in France During the Coronavirus Disease 2019 Pandemic",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Billioti De Gage",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Drouin",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Desplas",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Cuenot",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Dray-Spira",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Weill",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "JAMA Ophthalmol",
            "volume": "139",
            "issn": "",
            "pages": "240--242",
            "other_ids": {
                "DOI": [
                    "10.1001/jamaophthalmol.2020.5594"
                ]
            }
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "Referral Hospital in Milan",
            "authors": [],
            "year": 2021,
            "venue": "Retina",
            "volume": "41",
            "issn": "",
            "pages": "701--706",
            "other_ids": {
                "DOI": [
                    "10.1097/IAE.0000000000002941"
                ]
            }
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "The Impact of COVID-19 on Intravitreal Injection Compliance",
            "authors": [
                {
                    "first": "L",
                    "middle": [
                        "M"
                    ],
                    "last": "Wasser",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Weill",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Brosh",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Magal",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Potter",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Strassman",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "SN Compr Clin Med",
            "volume": "2",
            "issn": "",
            "pages": "2546--2555",
            "other_ids": {}
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Cramer",
                    "suffix": ""
                },
                {
                    "first": "\u00c1",
                    "middle": [],
                    "last": "Benedict",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Muszbek",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Keskinaslan",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [
                        "M"
                    ],
                    "last": "Khan",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Int J Clin Pract",
            "volume": "62",
            "issn": "",
            "pages": "76--87",
            "other_ids": {
                "DOI": [
                    "10.1111/j.1742-1241.2007.01630.x"
                ]
            }
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE",
            "authors": [
                {
                    "first": "Q",
                    "middle": [
                        "D"
                    ],
                    "last": "Nguyen",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "M"
                    ],
                    "last": "Brown",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "M"
                    ],
                    "last": "Marcus",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "S"
                    ],
                    "last": "Boyer",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Patel",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Feiner",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Ophthalmology",
            "volume": "119",
            "issn": "",
            "pages": "789--801",
            "other_ids": {
                "DOI": [
                    "10.1016/j.ophtha.2011.12.039"
                ]
            }
        },
        "BIBREF25": {
            "ref_id": "b25",
            "title": "Meta-analysis and review on the effect of bevacizumab in diabetic macular edema",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Goyal",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Lavalley",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "L"
                    ],
                    "last": "Subramanian",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Graefes Arch Clin Exp Ophthalmol",
            "volume": "249",
            "issn": "",
            "pages": "15--27",
            "other_ids": {}
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Cai",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "M"
                    ],
                    "last": "Bressler",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Curr Opin Ophthalmol",
            "volume": "28",
            "issn": "",
            "pages": "636--679",
            "other_ids": {}
        },
        "BIBREF29": {
            "ref_id": "b29",
            "title": "Visual outcomes in Eyes Lost to Follow Up with Diabetic Macular Edema treated with Anti-Vascular Endothelial Growth Factor",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Matsunaga",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Obeid",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "D"
                    ],
                    "last": "Wibbelsman",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Hsu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Invest Ophthalmol Vis Sci",
            "volume": "61",
            "issn": "",
            "pages": "4878--4878",
            "other_ids": {}
        },
        "BIBREF30": {
            "ref_id": "b30",
            "title": "Short-Term Effects of COVID-19-Related Deferral of Intravitreal Injection Visits",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Ashkenazy",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Goduni",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "E"
                    ],
                    "last": "Smiddy",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "Clin Ophthalmol",
            "volume": "15",
            "issn": "",
            "pages": "413--420",
            "other_ids": {
                "DOI": [
                    "10.2147/OPTH.S296345"
                ]
            }
        },
        "BIBREF31": {
            "ref_id": "b31",
            "title": "The Effect of Delay in Care Among Patients Requiring Intravitreal Injections",
            "authors": [
                {
                    "first": "W",
                    "middle": [],
                    "last": "Song",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "P"
                    ],
                    "last": "Singh",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "V"
                    ],
                    "last": "Rachitskaya",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Oph Retina",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.oret.2020.12.020"
                ]
            }
        },
        "BIBREF32": {
            "ref_id": "b32",
            "title": "Short term visual and structural outcomes of anti-vascular endothelial growth factor (anti-VEGF) treatment delay during the first COVID-19 wave: A pilot study",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "V"
                    ],
                    "last": "Naravane",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Mundae",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Santilli",
                    "suffix": ""
                },
                {
                    "first": "Fjgm",
                    "middle": [],
                    "last": "Van Kuijk",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Nazari",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "PLoS One",
            "volume": "16",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF34": {
            "ref_id": "b34",
            "title": "Delayed Intravitreal Anti-VEGF Therapy for Patients During the COVID-19 Lockdown: An Ethical Endeavor",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Elfalah",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "A"
                    ],
                    "last": "Alryalat",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Toro",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Rejdak",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Zweifel",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Nazzal",
                    "suffix": ""
                }
            ],
            "year": 2021,
            "venue": "Clin Ophthalmol",
            "volume": "15",
            "issn": "",
            "pages": "661--670",
            "other_ids": {
                "DOI": [
                    "10.2147/OPTH.S289068"
                ]
            }
        },
        "BIBREF35": {
            "ref_id": "b35",
            "title": "Impact of Intravitreal Ranibizumab Therapy on Vision Outcomes in Diabetic Macular Edema Patients: A Meta-Analysis",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Falc\u00e3o",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "OPH",
            "volume": "243",
            "issn": "",
            "pages": "243--54",
            "other_ids": {
                "DOI": [
                    "10.1159/000505070"
                ]
            }
        },
        "BIBREF36": {
            "ref_id": "b36",
            "title": "Factors influencing clinical outcomes in patients with diabetic macular edema treated with intravitreal ranibizumab: comparison between responder and non-responder cases",
            "authors": [
                {
                    "first": "Y-P",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "A-L",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "C-C",
                    "middle": [],
                    "last": "Chuang",
                    "suffix": ""
                },
                {
                    "first": "S-N",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Scientific Reports",
            "volume": "9",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1038/s41598-019-47241-1"
                ]
            }
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "D\u00e9crire le retentissement sur l'acuit\u00e9 visuelle et l'\u00e9paisseur centromaculaire apr\u00e8s arr\u00eat des injections intravitr\u00e9ennes d'anti-VEGF chez les patients diab\u00e9tiques marocains au cours de la pand\u00e9mie du Coronavirus. Et \u00e9tudier les facteurs pouvant \u00eatre associ\u00e9s \u00e0 l'aggravation. Mat\u00e9riel et m\u00e9thodes : Cette \u00e9tude transversale monocentrique a inclus les patients programm\u00e9s pour injections intravitr\u00e9ennes de Bevacizumab au cours de la p\u00e9riode du confinement (20 Mars 2020-20 Mai 2020) et qui n'en ont pas b\u00e9n\u00e9fici\u00e9. Ont \u00e9t\u00e9 recueillis : l'\u00e2ge, le sexe, l'anciennet\u00e9 du diab\u00e8te, le nombre d'injections re\u00e7ues avant le confinement, l'acuit\u00e9 visuelle en pr\u00e9-confinement et post-confinement ainsi que l'\u00e9paisseur centromaculaire pr\u00e9-confinement et post-confinement.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "Conclusion : Le report des injections intravitr\u00e9ennes au cours du confinement a eu des effets n\u00e9gatifs sur l'acuit\u00e9 visuelle et l'\u00e9paisseur centromaculaire des yeux avec OMD. Un report prolong\u00e9 des injections intravitr\u00e9ennes d'anti-VEGF chez les patients diab\u00e9tiques doit \u00eatre \u00e9vit\u00e9. Mots cl\u00e9s : Pand\u00e9mie COVID-19, Confinement COVID-19, OEd\u00e8me maculaire diab\u00e9tique, injections intravitr\u00e9ennes. Abstarct Purpose: To assess functional and anatomical consequences of the delay in intravitreal injections for diabetic macular edema (DME) patients during the corona virus pandemic lockdown in Morocco as well as to evaluate factors associated with disease progression. Patients and Methods: This cross-sectional study included DME patients who did not complete their scheduled intravitreal bevacizumab injections during the Lockdown period (March 20, 2020 to May 20, 2020). Data recorded included age, duration of diabetes, number of previous intravitreal injections, best-corrected visual acuity, and central macular thickness before and after the lockdown. Results: 154 eyes of 104 patients were analyzed. 57.8% were male. The mean age was 59.4 \u00b1 9.04 years. The mean duration of delay of intravitreal injections was 57.3 \u00b1 6.7 days. The mean number of intravitreal bevacizumab injections received before the lockdown was 2.29 \u00b1 2.1. Worsening of visual acuity was noted in 44.8% of patients and was associated with a lower number of intravitreal injections performed prior to the lockdown (p = 0.001) and with glycemic imbalance (p = 0.04). An increase in central macular thickness was noted in 26.6% of patients and was associated with a lower number of intravitreal injections (p = 0.038). Conclusion: The delay in intravitreal injections during the lockdown had negative effects on visual acuity and central macular thickness in eyes with DME. Prolonged delay in intravitreal anti-VEGF injections in diabetic patients should be avoided Keywords: COVID-19 Pandemic, COVID-19 lockdown, Diabetic macular edema, intravitreal injection. Introduction : Le Maroc enregistra le 02 Mars 2020 le premier cas d'infection au Coronovirus. [1] Le 20 mars 2020 l'\u00e9tat d'urgence sanitaire ainsi qu'un confinement g\u00e9n\u00e9ral ont \u00e9t\u00e9 impos\u00e9s. Les h\u00f4pitaux publiques ont d\u00fb r\u00e9organiser leurs activit\u00e9s afin d'accueillir les cas d'infection au Coronavirus. Toute activit\u00e9 jug\u00e9e non urgente a \u00e9t\u00e9 report\u00e9e. Le service d'ophtalmologie du CHU Hassan II de F\u00e8s est un service hospitalier de soins tertiaires assurant la plus grande partie des activit\u00e9s de r\u00e9tine m\u00e9dicale et chirurgicale dans la r\u00e9gion de F\u00e8s-Mekn\u00e8s. Au cours du confinement, seulement la chirurgie vitr\u00e9or\u00e9tinienne (pour d\u00e9collement de r\u00e9tine ou h\u00e9morragie du vitr\u00e9), la chirurgie de cataracte cong\u00e9nitale ou post-traumatique, la chirurgie filtrante, la r\u00e9paration des traumatismes oculaires, et les injections intravitr\u00e9ennes (pour glaucome n\u00e9ovasculaire, rub\u00e9ose irienne, DMLA exsudative, n\u00e9ovaisseaux du myope fort) ont \u00e9t\u00e9 maintenues. Toutes les autres activit\u00e9s ont \u00e9t\u00e9 report\u00e9es notamment les injections intravitr\u00e9ennes pour oed\u00e8me maculaire diab\u00e9tique (OMD) et oed\u00e8me maculaire sur occlusion veineuse r\u00e9tinienne.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "Mat\u00e9riel et m\u00e9thodes : Le cadre de l'\u00e9tude : Il s'agit d'une \u00e9tude transversale monocentrique men\u00e9e au service d'ophtalmologie du CHU HASSAN II de F\u00e8s Maroc. Ont \u00e9t\u00e9 inclus dans l'\u00e9tude tous les patients trait\u00e9s au sein de notre formation par injections intravitr\u00e9ennes de Bevacizumab pour OMD et qui ont \u00e9t\u00e9 contraints \u00e0 arr\u00eater leurs injections durant la p\u00e9riode du confinement g\u00e9n\u00e9ral (20 Mars 2020 au 20 Mai 2020). Ont \u00e9t\u00e9 exclus de l'\u00e9tude tous les patients recevant des injections intravitr\u00e9ennes d'autres mol\u00e9cules \u00e0 part le Bevacizumab et pour d'autres indications que l'OMD. Proc\u00e9dure de r\u00e9cup\u00e9ration des patients et recueil des donn\u00e9es : J o u r n a l P r e -p r o o f Les patients qui \u00e9taient programm\u00e9s pour injections intravitr\u00e9ennes du 20 Mars 2020 au 20 Mai 2020 (au cours du confinement) ont \u00e9t\u00e9 contact\u00e9s par t\u00e9l\u00e9phone. Tous ces patients avaient d\u00e9j\u00e0 re\u00e7u au moins une injection intravitr\u00e9enne de Bevacizumab pour OMD avant le confinement et \u00e9taient soit en phase d'induction ou sous r\u00e9gime Pro re nata (PRN). Une unit\u00e9 d'accueil \u00e0 l'entr\u00e9e de l'h\u00f4pital a \u00e9t\u00e9 instaur\u00e9e afin de v\u00e9rifier l'absence de signes d'infection au COVID-19 et la mesure de la temp\u00e9rature \u00e9tait syst\u00e9matique. Tous les patients contact\u00e9s ont b\u00e9n\u00e9fici\u00e9 d'une mesure de l'acuit\u00e9 visuelle et d'une tomographie \u00e0 coh\u00e9rence optique. Les donn\u00e9es recueillies sont l'\u00e2ge, le sexe, l'anciennet\u00e9 du diab\u00e8te, le nombre d'injections re\u00e7ues avant le confinement, l'acuit\u00e9 visuelle en pr\u00e9-confinement ainsi que l'\u00e9paisseur centromaculaire pr\u00e9confinement (recueillies \u00e0 partir du dernier examen ophtalmologique r\u00e9alis\u00e9 avant le confinement). L'acuit\u00e9 visuelle post-confinement ainsi que l'\u00e9paisseur centromaculaire post-confinement ont \u00e9t\u00e9 \u00e9galement recueillies. L'acuit\u00e9 visuelle a \u00e9t\u00e9 \u00e9valu\u00e9e en \u00e9chelle d\u00e9cimale puis convertie en Log MAR. L'aggravation fonctionnelle a \u00e9t\u00e9 d\u00e9finie par la perte d'une ligne ou plus. Alors que l'aggravation structurelle a \u00e9t\u00e9 d\u00e9finie par l'augmentation de l'\u00e9paisseur centromaculaire de plus de 10%. Analyse statistique : Des statistiques descriptives ont \u00e9t\u00e9 utilis\u00e9es pour d\u00e9crire les donn\u00e9es personnelles des patients et les caract\u00e9ristiques cliniques et tomographiques. Les fr\u00e9quences ont \u00e9t\u00e9 utilis\u00e9es pour pr\u00e9senter les variables qualitatives alors que les moyennes et les \u00e9carts types ont \u00e9t\u00e9 utilis\u00e9s pour pr\u00e9senter les variables quantitatives.L'\u00e9tude du lien entre l'aggravation de l'oed\u00e8me maculaire diab\u00e9tique et les diff\u00e9rents facteurs possibles a \u00e9t\u00e9 r\u00e9alis\u00e9e \u00e0 l'aide du test du KHI2 pour les variables qualitatives, tandis que l'analyse des variables quantitatives a \u00e9t\u00e9 r\u00e9alis\u00e9e par le test de Student.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF3": {
            "text": "Au total 104 patients suivis pour OMD ont \u00e9t\u00e9 revus en post-confinement, ce qui correspond \u00e0 154 yeux. 57,8% \u00e9taient des hommes avec une moyenne d'\u00e2ge de 59,4 \u00b1 9,04 ans. (Tableau 1) d'un d\u00e9s\u00e9quilibre glyc\u00e9mique en post-confinement chez 50,9% des patients.La dur\u00e9e moyenne d'arr\u00eat des injections intravitr\u00e9ennes est de 57,3 \u00b16,7 jours. Le nombre moyen d'injections intravitr\u00e9ennes de Bevacizumab re\u00e7ues avant le confinement a \u00e9t\u00e9 estim\u00e9 \u00e0 2,29 \u00b1 2,1.L'acuit\u00e9 visuelle avant l'arr\u00eat \u00e9tait de 0,79 \u00b1 0,46 LogMAR et 44,8% de nos patients ont pr\u00e9sent\u00e9 une aggravation fonctionnelle qui a \u00e9t\u00e9 associ\u00e9e au faible nombre d'injections intravitr\u00e9ennes de Bevacizumab r\u00e9alis\u00e9es avant le confinement (p = 0,001) ainsi qu'avec le d\u00e9s\u00e9quilibre du diab\u00e8te chez nos patients (p = 0,04). (Tableau 2) Caract\u00e9ristiques tomographiques : L'\u00e9paisseur centromaculaire avant l'arr\u00eat a \u00e9t\u00e9 estim\u00e9e \u00e0 552,55 \u00b1 117,86 et 26,6% des patients ont pr\u00e9sent\u00e9 une aggravation structurelle qui a \u00e9t\u00e9 aussi associ\u00e9e au faible nombre d'injections intravitr\u00e9ennes de Bevacizumab r\u00e9alis\u00e9es avant le confinement (p = 0,038). (Tableau 2) Discussion : Le but de cette \u00e9tude \u00e9tait d'\u00e9valuer les cons\u00e9quences fonctionnelles et structurelles secondaires au report des injections intravitr\u00e9ennes au cours des deux mois du confinement. La pand\u00e9mie du SARS-CoV-2 a constitu\u00e9 un dilemme pour la pratique de l'ophtalmologie vu le risque \u00e9lev\u00e9 de transmission de l'infection. [7] Essentiellement la conduite \u00e0 tenir vis-\u00e0-vis des injections intravitr\u00e9ennes qui concernent fr\u00e9quemment des sujets diab\u00e9tiques et \u00e2g\u00e9s susceptibles de d\u00e9velopper des formes graves de COVID-19. [8] Depuis le d\u00e9but de la pand\u00e9mie, plusieurs publications et recommandations ont \u00e9t\u00e9 \u00e9mises afin d'orienter la gestion des injections intravitr\u00e9ennes. [9,10] Par exemple, la soci\u00e9t\u00e9 fran\u00e7aise d'ophtalmologie a sugg\u00e9r\u00e9 le report des injections intravitr\u00e9ennes pour OMD et oed\u00e8me maculaire post-occlusion veineuse r\u00e9tinienne. [10] LaVision Academy a \u00e9galement sugg\u00e9r\u00e9 le report des injections pour OMD, mais en \u00e9vitant de d\u00e9passer 3 \u00e0 4 mois d'arr\u00eat.[9] Alors que Carnevali et al a \u00e9tabli des niveaux de priorit\u00e9 des injections selon l'indication et a consid\u00e9r\u00e9 un report de 30 \u00e0 40 jours sauf pour les patients monophtalmes.[11]",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "\uf0d8 Auteur 5 \u00e8me position : \uf0fc Abdellaoui Meryem, Professeur agr\u00e9g\u00e9, service d'ophtalmologie. H\u00f4pital Omar Drissi F\u00e8s, CHU Hassan II F\u00e8s. Facult\u00e9 de m\u00e9decine et de pharmacie de F\u00e8s. Universit\u00e9 Sidi Mohamed Ben Abdellah. \uf0fc Benatiya Andaloussi Idriss, Professeur de l'enseignement sup\u00e9rieur, service d'ophtalmologie. H\u00f4pital Omar Drissi F\u00e8s, CHU Hassan II F\u00e8s. Facult\u00e9 de m\u00e9decine et de pharmacie de F\u00e8s. Universit\u00e9 Sidi Mohamed Ben Abdellah. \uf0fc Adresse mail : idriss.benatiyaandaloussi@usmba.ac.ma",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "R\u00e9sultats : 154 yeux de 104 patients ont \u00e9t\u00e9 analys\u00e9s. 57,8% \u00e9taient des hommes avec une moyenne d'\u00e2ge de 59,4 \u00b1 9,04 ans. La dur\u00e9e moyenne d'arr\u00eat des injections intravitr\u00e9ennes est de 57,3 \u00b16,7 jours. Le nombre moyen d'injections intravitr\u00e9ennes de Bevacizumab re\u00e7ues avant le confinement a \u00e9t\u00e9 estim\u00e9 \u00e0 2,29 \u00b1 2,1. L'aggravation de l'acuit\u00e9 visuelle a \u00e9t\u00e9 not\u00e9e chez 44,8% de nos patients. Les",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}